CYTO — Altamira Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual balance sheet for Altamira Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	1.38	11.3	0.984	0.015	0.617
Net Total Accounts Receivable
Net Total Receivables	0.335	0.08	0.693	0.763	0.075
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	2.37	11.6	4.09	1.77	1.22
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	0.067	0.047	0.565	0.446	0.08
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	9.23	20.8	19.2	6.3	7.69
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	2.28	3.03	4.86	12.9	0.889
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Funded Status
Total Liabilities	3.19	4.03	6.13	14.6	1.24
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	6.04	16.8	13	-8.31	6.46
Total Liabilities & Shareholders' Equity	9.23	20.8	19.2	6.3	7.69
Total Common Shares Outstanding